Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | Director · President and CEO | May 29, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,771 |
Reported balance
After 2026-05-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 5,000 · Balance 40,771 F1: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period). F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period).
F2: Includes unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 1, 2026 20:37 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 5,000 | $3.05 | $15,257.50 |
DisclosureSEC source: 0001193125-26-251586 · ownership.xml · nonDerivative · entry 1 Vance Cary Guy · CIK 0001608992 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,771 F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period). F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period). F2 · balance_after: Includes unvested RSUs. Read SEC document |
| January 21, 2025 Filed Jun 5, 2025 21:00 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 4,295 | $0.00 Strike: $8.73 | $0.00 |
DisclosureSEC source: 0000950170-25-082466 · ownership.xml · derivative · entry 2 Vance Cary Guy · CIK 0001608992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,295 Underlying: Common Stock · 4,295 shares Expires 2035-01-21 F3 · derivative.exercise_price: On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025. Read SEC document |
| January 21, 2025 Filed Jun 5, 2025 21:00 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 10,022 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-082466 · ownership.xml · nonDerivative · entry 1 Vance Cary Guy · CIK 0001608992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,771 F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 23:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 3,943 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0000950170-24-070089 · ownership.xml · derivative · entry 2 Vance Cary Guy · CIK 0001608992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,943 Underlying: Common Stock · 3,943 shares Expires 2034-06-05 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 23:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 9,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-070089 · ownership.xml · nonDerivative · entry 1 Vance Cary Guy · CIK 0001608992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,749 F1 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:39 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 2,646 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001209191-23-035443 · doc4.xml · derivative · entry 4 Vance Cary Guy · CIK 0001608992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,646 Underlying: Common Stock · 2,646 shares Expires 2033-06-06 F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock. F6 · derivative.exercise_date: These Stock Options vest on the date 12 months following the grant date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:39 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 4,446 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001209191-23-035443 · doc4.xml · derivative · entry 3 Vance Cary Guy · CIK 0001608992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,446 Underlying: Common Stock · 4,446 shares Expires 2033-06-06 F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock. F5 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:39 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 6,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-035443 · doc4.xml · nonDerivative · entry 2 Vance Cary Guy · CIK 0001608992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,549 F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock. F4 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date. F3 · balance_after: Includes unvested RSUs. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:39 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 10,374 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-035443 · doc4.xml · nonDerivative · entry 1 Vance Cary Guy · CIK 0001608992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,374 F1 · shares: The reporting person may elect to acquire the Issuer's CHESS Depositary Interests ("CDIs") in place of common stock upon vesting of a Restricted Stock Unit ("RSU") or exercise of a Stock Option. CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of common stock and have all the rights and privileges of common stock. F2 · price: Represents an award of RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date. F3 · balance_after: Includes unvested RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.